Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.

Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 6;13:3923-3936. doi: 10.2147/COPD.S179293. eCollection 2018.

2.

Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations.

Kardos P, Beeh KM, Sent U, Mueck T, Gräter H, Michel MC.

BMC Pharmacol Toxicol. 2018 Jul 4;19(1):40. doi: 10.1186/s40360-018-0229-y.

3.

Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).

Beeh KM, Emirova A, Prunier H, Santoro D, Nandeuil MA.

Int J Chron Obstruct Pulmon Dis. 2018 May 25;13:1701-1711. doi: 10.2147/COPD.S168493. eCollection 2018.

4.

Correction to: Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis.

Di Marco F, Sotgiu G, Santus P, O'Donnell DE, Beeh KM, Dore S, Roggi MA, Giuliani L, Blasi F, Centanni S.

Respir Res. 2018 Apr 24;19(1):70. doi: 10.1186/s12931-018-0764-5.

5.

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis.

Di Marco F, Sotgiu G, Santus P, O'Donnell DE, Beeh KM, Dore S, Roggi MA, Giuliani L, Blasi F, Centanni S.

Respir Res. 2018 Jan 24;19(1):18. doi: 10.1186/s12931-018-0721-3. Review. Erratum in: Respir Res. 2018 Apr 24;19(1):70.

6.

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.

Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E.

Int J Chron Obstruct Pulmon Dis. 2017 Aug 24;12:2545-2558. doi: 10.2147/COPD.S143488. eCollection 2017.

7.

How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Fležar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Ställberg B, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):139-149. doi: 10.1164/rccm.201609-1794CI. Review.

8.
9.

The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease.

Beeh KM.

Tuberc Respir Dis (Seoul). 2016 Oct;79(4):241-247. Epub 2016 Oct 5. Review.

10.

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).

Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D, Gunstone A, Casamor R, Kostikas K, Aalamian-Mattheis M.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 28;11:1425-34. doi: 10.2147/COPD.S106127. eCollection 2016.

11.

The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).

Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L.

Int J Chron Obstruct Pulmon Dis. 2016 Feb 4;11:193-205. doi: 10.2147/COPD.S95055. eCollection 2016.

12.

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance.

Beeh KM, Kirsten AM, Dusser D, Sharma A, Cornelissen P, Sigmund R, Moroni-Zentgraf P, Dahl R.

J Aerosol Med Pulm Drug Deliv. 2016 Oct;29(5):406-415. Epub 2016 Feb 9.

13.

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.

O'Byrne PM, D'Urzo T, Beck E, Fležar M, Gahlemann M, Hart L, Blahova Z, Toorawa R, Beeh KM.

Respir Res. 2015 Aug 18;16:97. doi: 10.1186/s12931-015-0249-8.

14.
15.

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).

Vogelmeier CF, Asijee GM, Kupas K, Beeh KM.

Adv Ther. 2015 Jun;32(6):537-47. doi: 10.1007/s12325-015-0216-2. Epub 2015 Jun 23.

16.

Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.

Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H.

N Engl J Med. 2015 May 21;372(21):1987-95. doi: 10.1056/NEJMoa1411776. Epub 2015 May 17.

17.

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.

Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.

Pulm Pharmacol Ther. 2015 Jun;32:53-9. doi: 10.1016/j.pupt.2015.04.002. Epub 2015 May 6.

18.

Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD.

Cazzola M, Beeh KM, Price D, Roche N.

Pulm Pharmacol Ther. 2015 Apr;31:68-78. doi: 10.1016/j.pupt.2015.02.007. Epub 2015 Feb 26.

19.

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.

Beeh KM, Watz H, Puente-Maestu L, de Teresa L, Jarreta D, Caracta C, Garcia Gil E, Magnussen H.

BMC Pulm Med. 2014 Dec 23;14:209. doi: 10.1186/1471-2466-14-209.

20.

Longitudinal measurement of airway inflammation over one year in children and adults with intermittent asthma.

Pedersen F, Holz O, Kanniess F, Zielen S, Schulze J, Gillissen A, von Berg A, Berdel D, Beier J, Beeh K, Schnoor M, Magnussen H.

BMC Res Notes. 2014 Dec 17;7:925. doi: 10.1186/1756-0500-7-925.

Supplemental Content

Support Center